Epinastine clinical trials
How each study uses epinastine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Oct 2003 · ELESTAT · NDA 021565 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2001 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 3 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Boehringer Ingelheim (6) · Merck Sharp & Dohme LLC (3) · Santen Pharmaceutical Co., Ltd. (2) · Hom, Milton M., OD, FAAO (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Antihistamines source
- One of Histamine H1 Antagonists source
Studies
Open first, then newest update. How each study uses epinastine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic RhinitisCompletedPhase 2Merck Sharp & Dohme LLCNCT01382654Written as epinastine 0.1%How we know
- A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic RhinitisCompletedPhase 2Merck Sharp & Dohme LLCNCT00407927Written as Epinastine Nasal SprayHow we know
- Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic ConjunctivitisCompletedPhase 4Merck Sharp & Dohme LLCNCT00534794Written as ElestatHow we know
- Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01363700Written as DE-114 ophthalmic solutionHow we know
- Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02260050Written as WAL 801 CL dry syrup new formulationHow we know
- A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01363713Written as DE-114 ophthalmic solutionHow we know
- Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02182531Written as EpinastineHow we know
- WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic RhinitisCompletedPhase 3Boehringer IngelheimNCT02182544Written as WAL801CL dry syrupHow we know
- WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis PatientsCompletedPhase 3Boehringer IngelheimNCT02182557Written as WAL 801 CL Dry SyrupHow we know
- Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic RhinitisCompletedPhase 3Boehringer IngelheimNCT02182518Written as EpinastineHow we know
- WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis PatientsCompletedPhase 3Boehringer IngelheimNCT02182570Written as WAL 801 CL dry syrupHow we know
- Comparison of CL Wear Between Two Allergy DropsWithdrawnPhase 4Hom, Milton M., OD, FAAONCT00489398Written as epinastine HCL and olopatadine HCLHow we know
As the comparator · 1 — what is tested is compared with epinastine
Codes
What other systems call epinastine · ClinicalTrials.gg INT003335
- MeSH (NLM) C053090epinastineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q13WX941EFEPINASTINEConfirmed FDA, NLM, Wikidata
- RxNorm 39684Confirmed FDA, Wikidata
- Wikidata Q632405(RS)-epinastineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65515EpinastineOne source FDA
- DrugBank DB00751One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C053090 | epinastine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q13WX941EF | EPINASTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 39684 | — | Confirmed FDA, Wikidata |
| Wikidata | Q632405 | (RS)-epinastine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65515 | Epinastine | One source FDA |
| DrugBank | DB00751 | — | One source Wikidata |
Also registered as epinastine hydrochloride (UNII GFM415S5XL · RxNorm 236961).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.